Listed

Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2025

Filed with the SEC on Nov 6, 2025 and accepted by EDGAR at Nov 6, 2025, 16:16 ET.

Share

Management's discussion and analysis

As filed, 39,432 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States (“U.S.”), India, and Ireland.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. Risk Factors in our 2024 Annual Report on Form 10-K and under the heading Cautionary Note Regarding Forward-Looking Statements included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and nine months ended September 30, 2025 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2024 included in our 2024 Annual Report on Form 10-K.

Overview

We have three reportable segments: Affordable Medicines, Specialty, and AvKARE. Refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report on Form 10-K for a description of our segments.

The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our 2024 Annual Report on Form 10-K, as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

Inflation

While it is difficult to accurately measure the impact of inflation, we do not currently expect a material impact related to inflation for the year ending December 31, 2025. Notwithstanding our estimates, rising inflationary pressures due to higher input costs, including higher material, transportation, tariff impacts on supply, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

Trade Policy and Tariffs

We are subject to certain trade and tariff requirements imposed by the U.S. and various foreign governments. The great majority of our net sales rely on finished dosage forms (“FDF”) or active pharmaceutical ingredients (“API”) produced in the U.S. or India. We have limited reliance on imports from Europe and China, and no reliance on imports from Mexico or Canada.

During 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment. In addition, on April 14, 2025, the Department of Commerce Bureau of Industry and Security (“DOCBIS”) announced that it had initiated, as of April 1, 2025, a broad investigation under section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceuticals (i.e. FDF, API, key starting materials, derivatives, and medical countermeasures). There is currently an investigation into whether trade remedies such as tariffs should be imposed and covers both generic and brand products. On September 26, 2025, DOCBIS announced that, as of September 2, 2025, it had initiated a separate section 232 national security investigation of imports of personal protective equipment, medical consumables (including syringes and intravenous bags), and medical equipment (including devices).

Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry (i.e., increase costs, product availability, and supply chain disruptions). The Company is closely monitoring these tariff and trade developments and will take actions to reduce or minimize any material negative impact.

One Big Beautiful Bill Act

On July 4, 2025, President Trump signed the One Big Beautiful Bill Act, which includes a broad range of tax reform provisions affecting businesses, including, but not limited to, extending or making permanent certain business and international tax measures initially established under the 2017 Tax Cuts and Jobs Act and eliminating the requirement to capitalize and amortize U.S.-based research and experimental expenditures over five years, making these expenditures fully deductible in the period incurred. These provisions resulted in a reduction of the Company’s current income tax liabilities of $23.5 million during each of the three and nine months ended September 30, 2025.

Results of Operations

Comparison of Three Months Ended September 30, 2025 to Three Months Ended September 30, 2024

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 2025 2024 Change $%
Net revenue $784,513 $702,468 $82,045 11.7%
Cost of goods sold 510,539 432,910 77,629 17.9%
Gross profit 273,974 269,558 4,416 1.6%
Selling, general and administrative 137,815 118,692 19,123 16.1%
Research and development 63,352 61,097 2,255 3.7%
Intellectual property legal development expenses 2,437 1,967 470 23.9%
Restructuring and other charges 143 172 (29) (16.9)%
Credit related to legal matters, net — (149) 149 nm
Other operating income (117) (1,030) 913 (88.6)%
Operating income 70,344 88,809 (18,465) (20.8)%
Total other expense, net (75,567) (73,386) (2,181) 3.0%
Income before income taxes (5,223) 15,423 (20,646) (133.9)%
(Benefit from) provision for income taxes (23,355) 3,666 (27,021) nm
Net income $18,132 $11,757 $6,375 54.2%

nm - not meaningful

Net Revenue

Net revenue for the three months ended September 30, 2025 increased 11.7% from the prior year period, primarily due to:

  • Growth in our Affordable Medicines segment net revenue of $33.4 million, primarily due to new products launched in 2025 and 2024, which contributed $24.3 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
  • Growth in our Specialty segment net revenue of $9.6 million, primarily driven by increases of $17.1 million and $5.3 million of CREXONT® and UNITHROID®, respectively, partially offset by declines in RYTARY® revenues of $10.0 million and our non-promoted products.
  • Growth in our AvKARE segment net revenue of $39.0 million, primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

Cost of goods sold increased 17.9% for the three months ended September 30, 2025 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased sales volume from all segments, increased plant and freight costs, and impairment charges related to non-promoted products of $22.8 million, partially offset by manufacturing efficiencies.

Gross profit as a percentage of net revenue decreased to 34.9% for the three months ended September 30, 2025 from 38.4% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended September 30, 2025 increased 16.1% as compared to the prior year period, primarily due to increases in employee compensation, launch costs associated with CREXONT® and BREKIYA®, and expansion of our international sales and marketing organization.

Research and Development

Research and development (“R&D”) expenses for the three months ended September 30, 2025 increased 3.7% as compared to the prior year period, primarily due to increases in employee compensation and a $22.5 million in-licensing payment relating to Omalizumab. R&D expenses for the three months ended September 30, 2024 included $20.0 million in in-licensing payments associated with our exclusive license of Omalizumab.

Total Other Expense, Net

Total other expense, net for the three months ended September 30, 2025 decreased 3.0% as compared to the prior year period. The decrease was primarily driven by a $32.1 million period-over-period decrease in the tax receivable agreement liability (refer to Note 4. Income Taxes), partially offset by a $31.4 million in loss on refinancing (refer to Note 12. Debt) in the current period.

(Benefit from) Provision for Income Taxes

For the three months ended September 30, 2025, our (benefit from) provision for income taxes and effective tax rate were $(23.4) million and 447.2%, respectively, as compared to $3.7 million and 23.8%, respectively, for the three months ended September 30, 2024. The period-over-period changes in the (benefit from) provision for income taxes and effective tax rate primarily related to differences in jurisdictional mix of income, the utilization of net operating losses in the prior period, impact of the OBBBA and discrete items related to share-based compensation in the current period.

Affordable Medicines

The following table sets forth results of operations for our Affordable Medicines segment for the three months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 2025 2024 Change $%
Net revenue $460,741 $427,345 $33,396 7.8%
Cost of goods sold 280,463 249,342 31,121 12.5%
Gross profit 180,278 178,003 2,275 1.3%
Selling, general and administrative 37,173 30,951 6,222 20.1%
Research and development 55,124 57,099 (1,975) (3.5)%
Intellectual property legal development expenses 2,378 1,786 592 33.1%
Restructuring and other charges 90 17 73 nm
Credit related to legal matters, net — (149) 149 nm
Other operating income (117) — (117) nm
Operating income $85,630 $88,299 $(2,669) (3.0)%

nm - not meaningful

Net Revenue

Affordable Medicines net revenue for the three months ended September 30, 2025 increased 7.8% as compared to the prior year period, primarily due to new products launched in 2025 and 2024, which contributed $24.3 million of year-over-year growth, and strong volume growth, partially offset by price erosion.

Affordable Medicines cost of goods sold for the three months ended September 30, 2025 increased 12.5% as compared to the prior year period, primarily due to increased sales volume and increased plant and freight costs, partially offset by manufacturing efficiencies.

Affordable Medicines gross profit as a percentage of net revenue decreased to 39.1% for the three months ended September 30, 2025 from 41.7% in the prior year period primarily as a result of the factors noted above.

Selling, General, and Administrative

Affordable Medicines SG&A expense for the three months ended September 30, 2025 increased 20.1% as compared to the prior year period, primarily due to increases in employee compensation and expansion of our international sales and marketing organization.

Research and Development

Affordable Medicines R&D expenses for the three months ended September 30, 2025 decreased 3.5% as compared to the prior year period, primarily due to a reduction in project spend, partially offset by increases in employee compensation. The three months ended September 30, 2025 included a $22.5 million in-licensing payment relating to Omalizumab. R&D expenses for the three months ended September 30, 2024 included $20.0 million in in-licensing payments relating to Omalizumab.

Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 2025 2024 Change $%
Net revenue $125,240 $115,638 $9,602 8.3%
Cost of goods sold 73,808 52,342 21,466 41.0%
Gross profit 51,432 63,296 (11,864) (18.7)%
Selling, general and administrative 33,580 27,723 5,857 21.1%
Research and development 8,228 3,998 4,230 105.8%
Intellectual property legal development expenses 59 181 (122) nm
Other operating income — (1,030) 1,030 nm
Operating income $9,565 $32,424 $(22,859) (70.5)%

nm - not meaningful

Net Revenue

Specialty net revenue for the three months ended September 30, 2025 increased 8.3% compared to the prior year period, primarily driven by increases of $17.1 million and $5.3 million of CREXONT® and UNITHROID®, respectively, partially offset by declines in RYTARY® revenues of $10.0 million and our non-promoted products.

Specialty cost of goods sold for the three months ended September 30, 2025 increased 41.0% compared to the prior year period, primarily due to an impairment charge related to a non-promoted product of $22.1 million. Refer to Note 9. Goodwill and Other Intangible Assets for additional information.

Specialty gross profit as a percentage of net revenue decreased to 41.1% for the three months ended September 30, 2025 as compared to 54.7% in the prior year period primarily due to the impact of the impairment charge.

Selling, General, and Administrative

Specialty SG&A expense for the three months ended September 30, 2025 increased 21.1% as compared to the prior year period, primarily due to launch costs associated with CREXONT® and BREKIYA® and increases in employee compensation.

Research and Development

Specialty R&D expense for the three months ended September 30, 2025 increased 105.8% as compared to the prior year period, primarily due to higher project spend.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended September 30, 2025 and 2024 (in thousands):

Three Months Ended September 30, 2025 2024 Change $%
Net revenue $198,532 $159,485 $39,047 24.5%
Cost of goods sold 156,268 131,226 25,042 19.1%
Gross profit 42,264 28,259 14,005 49.6%
Selling, general and administrative 15,234 15,145 89 0.6%
Operating income $27,030 $13,114 $13,916 106.1%

Net Revenue

AvKARE net revenue for the three months ended September 30, 2025 increased 24.5% as compared to the prior year period, primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

AvKARE cost of goods sold for the three months ended September 30, 2025 increased 19.1% as compared to the prior year period, primarily due to higher sales in our government label channel, partially offset by decreased sales in our lower margin distribution channel.

Gross profit as a percentage of net revenue increased to 21.3% for the three months ended September 30, 2025 from 17.7% in the prior year period, primarily as a result of the factors noted above.

Comparison of Nine Months Ended September 30, 2025 to Nine Months Ended September 30, 2024

Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2025 and 2024 (in thousands):

Nine Months Ended September 30, 2025 2024 Change $%
Net revenue $2,204,441 $2,063,439 $141,002 6.8%
Cost of goods sold 1,388,323 1,305,874 82,449 6.3%
Gross profit 816,118 757,565 58,553 7.7%
Selling, general and administrative 380,369 347,749 32,620 9.4%
Research and development 151,356 136,449 14,907 10.9%
Intellectual property legal development expenses 6,221 3,993 2,228 55.8%
Restructuring and other charges 1,738 1,862 (124) (6.7)%
(Credit) charges related to legal matters, net (390) 94,909 (95,299) (100.4)%
Other operating income (5,239) (930) (4,309) nm
Operating income 282,063 173,533 108,530 62.5%
Total other expense, net (198,089) (213,227) 15,138 (7.1)%
Income (loss) before income taxes 83,974 (39,694) 123,668 nm
Provision for income taxes 5,614 13,440 (7,826) (58.2)%
Net income (loss) $78,360 $(53,134) $131,494 nm

nm - not meaningful

Net Revenue

Net revenue for the nine months ended September 30, 2025 increased 6.8% from the prior year period primarily due to:

  • Growth in our Affordable Medicines segment net revenue of $62.9 million, primarily due to new products launched in 2025 and 2024, which contributed $98.1 million of year-over-year growth, and strong volume growth, partially offset by price erosion.
  • Growth in our Specialty segment net revenue of $36.7 million, primarily driven by increases of $37.4 million and $13.1 million of CREXONT® and UNITHROID®, respectively, partially offset by declines in RYTARY® revenues of $6.1 million and our non-promoted products. In addition, there was a period-over-period decrease of $6.0 million in out-licensing revenue associated with IPX203.
  • Growth in our AvKARE segment net revenue of $41.4 million, primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

Cost of Goods Sold and Gross Profit

Cost of goods sold for the nine months ended September 30, 2025 increased 6.3% compared to the prior year period. The increase in cost of goods sold was primarily due to increased sales volume from all segments, impairment charges related to non-promoted products of $22.8 million, increased amortization related to CREXONT® and increased plant and freight costs, partially offset by manufacturing efficiencies.

Gross profit as a percentage of net revenue increased to 37.0% for the nine months ended September 30, 2025 from 36.7% in the prior year period, primarily as a result of the factors noted above.

Selling, General, and Administrative

SG&A expenses for the nine months ended September 30, 2025 increased 9.4% as compared to the prior year period, primarily due to increases in employee compensation and launch costs associated with CREXONT® and BREKIYA®.

Research and Development

R&D expenses for the nine months ended September 30, 2025 increased 10.9% as compared to the prior year period, primarily due to increases in employee compensation, increase in project spend and increase in in-licensing and upfront milestone payments.

(Credit) Charges Related to Legal Matters, Net

For the nine months ended September 30, 2024, (credit) charges related to legal matters, net of $94.9 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to Note 16. Commitments and Contingencies for additional information.

Other Operating Income

Other operating income for the nine months ended September 30, 2025 was primarily comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector (the “PLI Scheme”).

Total Other Expense, Net

Total other expense, net for the nine months ended September 30, 2025 decreased 7.1% as compared to the prior year period. The decrease was driven by a period-over-period decrease in the tax receivable agreement liability of $32.4 million (refer to Note 4. Income Taxes) and a $12.1 million period-over-period decrease in interest expense as a result of lower rates and lower amounts outstanding on our variable-rate debt, partially offset by a $31.4 million in loss on refinancing in the third quarter of 2025.

Provision for Income Taxes

For the nine months ended September 30, 2025, our provision for income taxes and effective tax rate were $5.6 million and 6.7%, respectively, as compared to $13.4 million and (33.9)%, respectively, for the nine months ended September 30, 2024. The period-over-period changes in the provision for income taxes and effective tax rate primarily related to differences in jurisdictional mix of income, the utilization of net operating losses in the prior period, impact of the OBBBA and discrete items related to share-based compensation in the current period.

Affordable Medicines

The following table sets forth results of operations for our Affordable Medicines segment for the nine months ended September 30, 2025 and 2024 (in thousands):

Nine Months Ended September 30, 2025 2024 Change $%
Net revenue $1,308,874 $1,245,967 $62,907 5.0%
Cost of goods sold 775,742 750,167 25,575 3.4%
Gross profit 533,132 495,800 37,332 7.5%
Selling, general and administrative 105,114 95,663 9,451 9.9%
Research and development 128,003 123,173 4,830 3.9%
Intellectual property legal development expenses 6,069 3,778 2,291 60.6%
Restructuring and other charges 773 70 703 nm
(Credit) charges related to legal matters, net (390) 94,909 (95,299) (100.4)%
Other operating income (5,239) — (5,239) nm
Operating income $298,802 $178,207 $120,595 67.7%

nm - not meaningful

Net Revenue

Affordable Medicines net revenue for the nine months ended September 30, 2025 increased 5.0% as compared to the prior year period, primarily due to new products launched in 2025 and 2024, which contributed $98.1 million of year-over-year growth, and strong volume growth, partially offset by price erosion.

Affordable Medicines cost of goods sold for the nine months ended September 30, 2025 increased 3.4% as compared to the prior year period, primarily due to increased sales volume and increased plant and freight costs, partially offset by manufacturing efficiencies.

Affordable Medicines gross profit as a percentage of net revenue increased to 40.7% for the nine months ended September 30, 2025 from 39.8% in the prior year period, primarily as a result of the factors noted above.

Selling, General, and Administrative

Affordable Medicines SG&A expense for the nine months ended September 30, 2025 increased 9.9% as compared to the prior year period, primarily due to increases in employee compensation, costs of our international expansion, and shipping costs.

Research and Development

Affordable Medicines R&D expenses for the nine months ended September 30, 2025 increased 3.9% as compared to the prior year period, primarily due to increases in employee compensation and in-licensing and upfront milestone payments, partially offset by reduced project spend.

(Credit) Charges Related to Legal Matters, Net

For the nine months ended September 30, 2024, (credit) charges related to legal matters, net of $94.9 million were primarily associated with a settlement in principle on the primary financial terms for a nationwide resolution to the opioids cases that have been filed and that might have been filed against us by political subdivisions and Native American tribes across the U.S. Refer to Note 16. Commitments and Contingencies for additional information.

Other Operating Income

Other operating income for the nine months ended September 30, 2025 was primarily comprised of income earned from the PLI Scheme.

Specialty

The following table sets forth results of operations for our Specialty segment for the nine months ended September 30, 2025 and 2024 (in thousands):

Nine Months Ended September 30, 2025 2024 Change $%
Net revenue $361,580 $324,913 $36,667 11.3%
Cost of goods sold 182,686 143,284 39,402 27.5%
Gross profit 178,894 181,629 (2,735) (1.5)%
Selling, general and administrative 94,872 79,529 15,343 19.3%
Research and development 23,353 13,276 10,077 75.9%
Intellectual property legal development expenses 152 215 (63) nm
Restructuring and other charges 471 1,024 (553) (54.0)%
Other operating income — (930) 930 nm
Operating income $60,046 $88,515 $(28,469) (32.2)%

nm - not meaningful

Net Revenue

Specialty net revenue for the nine months ended September 30, 2025 increased 11.3% as compared to the prior year period, primarily driven by increases of $37.4 million and $13.1 million of CREXONT® and UNITHROID®, respectively, partially offset by declines in RYTARY® revenues of $6.1 million and our non-promoted products. In addition, there was a period-over-period decrease of $6.0 million in out-licensing revenue associated with IPX203.

Specialty cost of goods sold for the nine months ended September 30, 2025 increased 27.5% as compared to the prior year period, primarily due to an impairment charge related to non-promoted product of $22.1 million (refer to Note 9. Goodwill and Other Intangible Assets for additional information), increases in amortization related to CREXONT® and increased sales volume.

Specialty gross profit as a percentage of net revenue decreased to 49.5% for the nine months ended September 30, 2025 as compared to 55.9%, primarily as a result of the factors noted above.

Selling, General, and Administrative

Specialty SG&A expense for the nine months ended September 30, 2025 increased 19.3% as compared to the prior year period, primarily due to launch costs associated with CREXONT® and BREKIYA® and increases in employee compensation.

Research and Development

Specialty R&D expenses for the nine months ended September 30, 2025 increased 75.9% as compared to the prior year period, primarily due to increased in-licensing and upfront milestone payments of $3.0 million and higher project spend.

AvKARE

The following table sets forth results of operations for our AvKARE segment for the nine months ended September 30, 2025 and 2024 (in thousands):

Nine Months Ended September 30, 2025 2024 Change $%
Net revenue $533,987 $492,559 $41,428 8.4%
Cost of goods sold 429,895 412,423 17,472 4.2%
Gross profit 104,092 80,136 23,956 29.9%
Selling, general and administrative 46,007 44,694 1,313 2.9%
Operating income $58,085 $35,442 $22,643 63.9%

Net Revenue

AvKARE net revenue for the nine months ended September 30, 2025 increased 8.4% as compared to the prior year period primarily driven by growth in our government label channel resulting from new product introductions, partially offset by a decline in our lower margin distribution channel.

Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the nine months ended September 30, 2025 increased 4.2% as compared to the prior year period primarily due to higher sales in our government label channel and an increase in the inventory provision, partially offset by decreased sales in our lower margin distribution channel.

Gross profit as a percentage of net revenue increased to 19.5% for the nine months ended September 30, 2025 from 16.3% in the prior year period, primarily as a result of the factors noted above.

Selling, General and Administrative

AvKARE SG&A expense for the nine months ended September 30, 2025 increased 2.9% as compared to the prior year period, primarily due to increases in employee compensation and shipping costs.

Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements as discussed and defined in Note 12. Debt in this Quarterly Report on Form 10-Q and in Note 15. Debt in our 2024 Annual Report on Form 10-K.

On April 9, 2025, we executed an amendment to the Amended Rondo Revolving Credit Facility that, among other things, (i) increased the aggregate revolving commitment from $70 million to $125 million, (ii) increased the letter of credit commitment from $60 million to $90 million, and (iii) extended the maturity to April 9, 2030.

On August 1, 2025, we borrowed $2.1 billion under new seven-year term loans (the “Term Loan Due 2032”) pursuant to an amendment to the Term Loan Credit Agreement and completed a private offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 at par (the “Senior Notes Due 2032”). We also entered into an amendment to the New Revolving Credit Facility (the “Amended New Revolving Credit Facility”). We used the net proceeds of the Term Loan Due 2032 and the Senior Notes due 2032 to refinance the Term Loan Due 2028 in full, repay outstanding amounts borrowed under the New Revolving Credit Facility in full, and pay related fees, premiums and expenses.

As of September 30, 2025, we had access to $595.2 million of available capacity under the Amended New Revolving Credit Facility and $83.0 million of available capacity under the Amended Rondo Revolving Credit Facility.

We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, the impact of international trade policy, including tariffs, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. Our primary uses of capital resources are to fund operating activities, including R&D expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, spending on production facility expansions, capital equipment, acquisitions, and legal settlements.

We estimate that we will invest approximately $120.0 million during 2025 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology, and facilities. Our 2025 estimate includes capital expenditures for our collaboration and supply agreement with Metsera, Inc. (“Metsera”), of which we expect Metsera to reimburse us approximately $20.0 million. We expect such reimbursements to primarily be included in our cash flows from financing activities.

Debt Instruments

Over the next 12 months, we expect to make substantial payments, including monthly interest and quarterly principal amounts for our Term Loan Due 2032, semi-annual interest payments on our Senior Notes Due 2032, and contractual payments for leased premises. Refer to Note 12. Debt in this Quarterly Report on Form 10-Q and Note 15. Debt, Note 17. Leases, and Commitments and Contractual Obligations under Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report on Form 10-K for additional information.

Settlement in Principle on Nationwide Civil Prescription Opioid Litigation

In late April 2024, we reached a settlement in principle on the primary financial terms, with no admission of wrongdoing, for a nationwide resolution to the opioids cases that have been filed and that might have been filed by Attorneys General, political subdivisions and Native American tribes. During July 2025, we deposited an aggregate of $24.2 million into dedicated accounts as a step in the process to finalize a definitive settlement agreement. These deposits remain our property until a definitive settlement agreement is reached and the funds are used to make the first installment payment. Refer to Note 16. Commitments and Contingencies for additional information.

Tax Receivable Agreement

As part of the Reorganization (as defined in Note 1. Nature of Operations in our 2024 Annual Report on Form 10-K), the tax receivable agreement (“TRA”) was amended to reduce our future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of September 30, 2025, the contingent TRA liability, including the impact of the amendment, was approximately $141.4 million. During the nine months ended September 30, 2025, we made payments of $3.0 million, associated with the TRA.

The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of our taxable income, and the corporate tax rate in effect at the time of realization of our taxable income. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to our obligation to make TRA payments in advance of tax benefits being realized. For further information, including our recognized current and long-term liabilities for the TRA, refer to Note 4. Income Taxes in this Quarterly Report on Form 10-Q and Item 1A. Risk Factors and Note 6. Income Taxes in our 2024 Annual Report on Form 10-K.

Tax-Related and Other Distributions

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the nine months ended September 30, 2025 and 2024, we made cash tax and other distributions of $38.8 million and $14.4 million, respectively, to the AvKARE Sellers.

Cash Balances

As of September 30, 2025, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

Cash Flows

The following table sets forth our summarized, consolidated cash flows for the nine months ended September 30, 2025 and 2024 (in thousands):

Net cash provided by (used in): Nine Months Ended September 30, 2025 2024 Change $%
Operating activities $209,677 $177,021 $32,656 18.4%
Investing activities (66,809) (46,937) (19,872) 42.3%
Financing activities (21,410) (150,587) 129,177 (85.8)%
Effect of exchange rate changes on cash (1,471) (259) (1,212) nm
Net increase (decrease) in cash, cash equivalents, and restricted cash $119,987 $(20,762) $140,749 nm

nm - not meaningful

Cash Flows from Operating Activities

Net cash provided by operating activities was $209.7 million for the nine months ended September 30, 2025 as compared to $177.0 million in the prior year period. Excluding the $52.4 million Opana ER® antitrust litigation settlement payment made in the prior year period, net cash from operating activities decreased period-over-period as increases in cash earnings and lower interest rates in the current period were offset by changes in working capital.

Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2025 was $66.8 million as compared to $46.9 million in the prior year period. The period-over-period increase in net cash used in investing activities was primarily due to an increase in capital expenditures and deposits for future acquisition of property, plant, and equipment in the current period.

Cash Flows from Financing Activities

Net cash used in financing activities was $21.4 million for the nine months ended September 30, 2025 as compared to $150.6 million in the prior year period. The period-over-period decrease in cash used in financing activities was primarily due to: (i) a period-over-period net increase in cash inflows from debt of $117.8 million, primarily as a result of the refinancing of our debt in the current period (refer to Note 12. Debt in this Quarterly Report on Form 10-Q), (ii) repayment of notes payable - related party of $44.2 million in the prior year period, and (iii) cash received from an alliance party of $5.6 million in the nine months ended September 30, 2025, partially offset by (A) a period-over-period increase of $24.4 million in tax and other cash distributions to non-controlling interests and (B) a period-over-period increase in employee payroll tax withholdings on restricted stock unit and performance stock unit vesting of $14.4 million.

Commitments and Contractual Obligations

Our contractual obligations are set forth in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our 2024 Annual Report on Form 10-K. As of September 30, 2025, there have been no material changes to the disclosure presented in our 2024 Annual Report on Form 10-K, except for the changes to our debt obligations discussed above under the header Liquidity and Capital Resources and Note 12. Debt in this Quarterly Report on Form 10-Q.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2025.

Critical Accounting Policies and Estimates

For a discussion of our critical accounting policies and estimates, see Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2024 Annual Report on Form 10-K.

Recently Issued Accounting Standards

Recently issued accounting standards are discussed in Note 1. Summary of Significant Accounting Policies.

Market risk

As filed, 198 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There has not been any material change in our assessment of market risk as set forth in Item 7A. Quantitative and Qualitative Disclosures About Market Risk, in our 2024 Annual Report on Form 10-K.

Controls and procedures

As filed, 2,885 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2025.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2025, there were no changes in our internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

Risk factors

As filed, 1,207 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Other than set forth below, there have been no material changes to the disclosures presented in our 2024 Annual Report on Form 10-K under Item 1A. Risk Factors.

A U.S. Government Shutdown Could Adversely Impact Our Regulatory, Operational and Financial Performance

We rely heavily on timely interactions with the U.S. Food and Drug Administration, the Drug Enforcement Administration, and other agencies of the U.S. Federal Government for, among other things, new product approvals, procurement quotas for controlled substances, facility inspections, and regulatory guidance. During a government shutdown, delays in these interactions could negatively impact our regulatory, operational and financial performance.

Additionally, our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs. Interruptions in government contracting and procurement processes, and slower payment cycles to distributors which AvKARE uses to do business with these governmental agencies, could also negatively impact our operational and financial performance.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-07-01 to 2025-09-30$784.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2025-01-01 to 2025-09-30$2.20bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-07-01 to 2025-09-30$510.5mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2025-01-01 to 2025-09-30$1.39bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2025-07-01 to 2025-09-30$274.0mus-gaap:GrossProfit
Gross profit9 months2025-01-01 to 2025-09-30$816.1mus-gaap:GrossProfit
Research and development3 months2025-07-01 to 2025-09-30$63.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2025-01-01 to 2025-09-30$151.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-07-01 to 2025-09-30$137.8mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2025-01-01 to 2025-09-30$380.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-07-01 to 2025-09-30$70.3mus-gaap:OperatingIncomeLoss
Operating income9 months2025-01-01 to 2025-09-30$282.1mus-gaap:OperatingIncomeLoss
Income tax3 months2025-07-01 to 2025-09-30−$23.4mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2025-01-01 to 2025-09-30$5.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-07-01 to 2025-09-30$2.4mus-gaap:NetIncomeLoss
Net income9 months2025-01-01 to 2025-09-30$37.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-07-01 to 2025-09-30$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2025-01-01 to 2025-09-30$0.11us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-07-01 to 2025-09-30$0.01us-gaap:EarningsPerShareBasic
Basic EPS9 months2025-01-01 to 2025-09-30$0.12us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-07-01 to 2025-09-30324,754,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2025-01-01 to 2025-09-30323,704,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2025-01-01 to 2025-09-30$209.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2025-01-01 to 2025-09-30$48.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-09-30$201.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-09-30$1.84bnus-gaap:AssetsCurrent
Total assetsAt period end2025-09-30$3.60bnus-gaap:Assets
Current liabilitiesAt period end2025-09-30$862.1mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2025-09-30$2.57bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-09-30$7.2mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-09-30−$109.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-25-000062. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.